The Maryland Prescription Drug Affordability Board (PDAB) is an independent state agency working to protect Marylanders—and the broader health care system—from the burden of high prescription drug costs. To do this, the PDAB conducts Cost Review Studies to identify medications that pose affordability challenges and can recommend solutions, including setting upper payment limits to reduce costs.

The Board is currently reviewing six high-impact drugs—Farxiga, Jardiance, Ozempic, Trulicity, Dupixent, and Skyrizi—and expects to complete Cost Review Studies starting this spring. If any of these drugs are found to create affordability challenges, the Board will begin the Policy Review Process as early as this summer.

The PDAB has the authority to set upper payment limits that apply to state and local governments—and we’re looking for municipal partners interested in exploring these savings opportunities. Together, we can make prescription drugs more affordable for our communities.

To learn more or express interest in partnering, please contact the PDAB team at support.pdab@maryland.gov.